[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641411":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":42,"centralContacts":47,"locations":53,"responsibleParty":73,"collaborators":76,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":104,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":26,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":56,"whyStopped":26,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Corticosteroid and Lidocaine Injection","EXPERIMENTAL","Participants receive 1-3 ultrasound-guided peritendinous injections of Depo-Medrol (methylprednisolone acetate 40 mg) combined with lidocaine. All participants receive one injection at baseline; up to two additional injections may be given within the first 8 weeks at intervals of 4 weeks if predefined criteria are met.",[13,14],"Other: Standard care","Drug: Depo-Medrol (methylprednisolone acetate 40 mg) combined with lidocaine",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo Injection","PLACEBO_COMPARATOR","Participants receive 1-3 ultrasound-guided peritendinous placebo injections consisting of lidocaine only. All participants receive one injection at baseline; up to two additional injections may be given within the first 8 weeks at intervals of at least 4 weeks if predefined criteria are met.",[13,20],"Drug: placebo injections consisting of lidocaine only",[22,27,35],{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"Standard care","Education, load management advice, and a structured progressive calf-muscle strengthening exercise programme supported by an online website.",[9,16],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Depo-Medrol (methylprednisolone acetate 40 mg) combined with lidocaine","Participants receive 1-3 ultrasound-guided peritendinous injections of Depo-Medrol (methylprednisolone acetate 40 mg) combined with lidocaine.",[9],[33,34],"Drug: Methylprednisolone acetate 40 mg + Lidocaine 10 mg","Depo-Medrol + Lidocaine",{"type":28,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"placebo injections consisting of lidocaine only","Participants receive 1-3 ultrasound-guided peritendinous placebo injections consisting of lidocaine onl",[16],[40,41],"Drug: Lidocaine 10 mg","Placebo injection",[43],{"name":44,"affiliation":45,"role":46},"Robert Jan de Vos, MD, PhD","Erasmus Medical Centre","PRINCIPAL_INVESTIGATOR",[48],{"name":49,"role":50,"phone":51,"phoneExt":26,"email":52},"Kristel van Abswoude, MD","CONTACT","+31 6 49326353","aspire@erasmusmc.nl",[54],{"facility":55,"status":56,"city":57,"state":26,"zip":26,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Erasmus MC","RECRUITING","Rotterdam","Netherlands","NL",{"type":61,"coordinates":62},"Point",[63,64],4.47917,51.9225,{"lat":64,"lon":63},[67,69],{"name":68,"role":50,"phone":51,"phoneExt":26,"email":52},"k van Abswoude, MD",{"name":70,"role":50,"phone":71,"phoneExt":26,"email":72},"R.J de Vos, MD\u002FPhD","+31 10 7040136","r.devos@erasmusmc.nl",{"type":46,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Adam Weir","Primary researcher",[77,79,81,83,85,87,89,91,94,96,98,100],{"name":78,"class":6},"ZonMw: The Netherlands Organisation for Health Research and Development",{"name":80,"class":6},"Amsterdam UMC",{"name":82,"class":6},"UMC Utrecht",{"name":84,"class":6},"Haaglanden Medical Centre",{"name":86,"class":6},"Gelderse Vallei Hospital",{"name":88,"class":6},"Isala",{"name":90,"class":6},"Bergman Clinics",{"name":92,"class":93},"Dutch Association of Sports Medicine (VSG)","UNKNOWN",{"name":95,"class":93},"Dutch Orthopaedic Association (NOV)",{"name":97,"class":93},"Dutch College of General Practitioners (NHG Musculoskeletal Care)",{"name":99,"class":93},"International Trial Advisory Board",{"name":101,"class":93},"Patient Panel","100641411","phase-3-the-aspire-trial-achilles-tendinopathy-treated-with-corticosteroid-injections-100641411",false,"NCT07650396","The ASPIRE Trial: AchilleS tendinoPathy Treated With cortIcosteRoid injEctions","ASPIRE","Inclusion Criteria:\n\n* Age 18-65 years\n* Clinically diagnosed midportion Achilles tendinopathy confirmed by ultrasound\n* Symptoms for at least 6 months\n* Persistent complaints despite standard care, including education, load management advice and at least 3 months of exercise therapy \u002F exercise programme\n\nExclusion Criteria:\n\n* • Clinical suspicion of insertional Achilles tendinopathy\n\n  * Clinical suspicion of Achilles tendon rupture\n  * Clinical suspicion of plantar flexor tenosynovitis\n  * Clinical suspicion of sural nerve pathology\n  * Clinical suspicion of peroneal tendon subluxation or peroneal tendinopathy\n  * Clinical suspicion of posterior ankle impingement syndrome\n  * Suspected systemic\u002Finflammatory disorder as cause of symptoms\n  * Any condition preventing participation in active exercise programme\n  * History of Achilles tendon rupture of index tendon\n  * Previous local corticosteroid injection on index Achilles tendon\n  * Previous surgery on index Achilles tendon\n  * Refusal to undergo one of the study treatments\n  * Local skin infection, suspected systemic infection with fever, or other medical condition compromising injection safety\n  * Vitamin K antagonist use with INR \\>3.0 within 3 days before injection or unknown INR\n  * Current pregnancy or breastfeeding\n  * Medication-induced tendon pathology (quinolones or statins related to symptom onset)\n  * Inability to provide informed consent\n  * Participation in another concomitant interventional programme for Achilles tendinopathy\n  * Known hypersensitivity or allergy to Depo-Medrol or Lidocaine\n  * Participants with unstable or poorly controlled diabetes mellitus may be excluded at investigator discretion for safety reasons.","ALL","18 Years","65 Years",{"count":113,"type":114},276,"ESTIMATED","INTERVENTIONAL",[117],"PHASE3","Achilles tendinopathy is a common and often persistent tendon disorder associated with pain, impaired function, and reduced participation in physical activities. Standard care consists of education, load management advice, and progressive calf-strengthening exercises, yet about half of patients remain symptomatic. Corticosteroid injections are frequently used in clinical practice, but evidence on long-term efficacy and safety remains inconclusive. The ASPIRE trial is a multicentre, randomized, double-blind, placebo-controlled phase III trial evaluating whether 1-3 ultrasound-guided peritendinous corticosteroid injections added to standard care are safe and more effective than placebo injections plus standard care in adults with chronic midportion Achilles tendinopathy. The primary outcomes are change in VISA-A score over 1 year and incidence of full-thickness Achilles tendon rupture during 1-year follow-up.",[120],"Achilles Tendinopathy (AT)",[122,123,41,124,125,126,127,128],"Corticosteroid injection","Lidocaine","Exercise therapy","Ultrasound-guided injection","Methylprednisolone acetate","Depo-Medrol","VISA-A","2026-06-16",{"date":131,"type":132},"2026-06-18","ACTUAL",{"date":134,"type":132},"2026-06-03",{"date":136,"type":114},"2028-10-31",{"name":5,"class":6},1]